Pax9 and Gbx2 interact in the pharyngeal endoderm to control cardiovascular cevelopment. by Stothard CA et al.
 J. Cardiovasc. Dev. Dis. 2020, 7, 20; doi:10.3390/jcdd7020020 www.mdpi.com/journal/jcdd 
Article 
Pax9 and Gbx2 Interact in the Pharyngeal Endoderm 
to Control Cardiovascular Development 
Catherine A. Stothard 1, Silvia Mazzotta 1, Arjun Vyas 1, Jurgen E. Schneider 2, Timothy J. Mohun 3,  
Deborah J. Henderson 1, Helen M. Phillips 1 and Simon D. Bamforth 1,* 
1 Newcastle University Biosciences Institute, Centre for Life, Newcastle-upon-Tyne NE1 3BZ, UK; 
catherinestothard@gmail.com (C.A.S.); silvia.mazzotta@abdn.ac.uk (S.M.); A.Vyas1@newcastle.ac.uk (A.V.); 
deborah.henderson@newcastle.ac.uk (D.J.H.); helen.phillips@newcastle.ac.uk (H.M.P.) 
2 Biomedical Imaging, University of Leeds, Leeds LS2 9JT, UK; J.E.Schneider@leeds.ac.uk 
3 The Francis Crick Institute, London NW1 1AT, UK; tim.mohun@gmail.com 
* Correspondence: simon.bamforth@newcastle.ac.uk; Tel.: +0044-191-241-8764 
Received: 25 March 2020; Accepted: 19 May 2020; Published: 25 May 2020 
Abstract: The correct formation of the aortic arch arteries depends on a coordinated and regulated 
gene expression profile within the tissues of the pharyngeal arches. Perturbation of the gene 
regulatory networks in these tissues results in congenital heart defects affecting the arch arteries 
and the outflow tract of the heart. Aberrant development of these structures leads to interruption of 
the aortic arch and double outlet right ventricle, abnormalities that are a leading cause of morbidity 
in 22q11 Deletion Syndrome (DS) patients. We have recently shown that Pax9 functionally interacts 
with the 22q11DS gene Tbx1 in the pharyngeal endoderm for 4th pharyngeal arch artery 
morphogenesis, with double heterozygous mice dying at birth with interrupted aortic arch. Mice 
lacking Pax9 die perinatally with complex cardiovascular defects and in this study we sought to 
validate further potential genetic interacting partners of Pax9, focussing on Gbx2 which is down-
regulated in the pharyngeal endoderm of Pax9-null embryos. Here, we describe the Gbx2-null 
cardiovascular phenotype and demonstrate a genetic interaction between Gbx2 and Pax9 in the 
pharyngeal endoderm during cardiovascular development. 
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1. Introduction 
Normal morphogenesis of the mammalian heart and aortic arch arteries is controlled by a 
complex interaction of tissues and gene expression. Genetic mutations that alter heart development 
result in congenital heart defects which affect nearly 1% of the population, and result in structural 
defects to the heart and its associated great vessels [1]. Conotruncal defects affecting the outflow tract 
(OFT) of the heart and the aortic arch arteries are a major feature in 22q11 deletion syndrome (DS) 
[2], and of the 45 genes haploinsufficient in these patients, TBX1 is thought to be the most important 
for cardiovascular development [3–5]. The OFT is formed from cells of the second heart field (SHF), 
a group of progenitor cells located in the splanchnic mesoderm that migrate to the heart and 
subsequently continue to provide progenitors to the heart throughout embryogenesis [6]. Initially 
formed as a common vessel, the OFT divides into the aorta and pulmonary trunk, and these two 
vessels separate and rotate around each other as the aorticopulmonary septal complex spirals 
caudally. Septation is completed by the fusion of the interventricular septum with the OFT 
endocardial cushions of the atrioventricular canal [7] and requires a contribution from neural crest 
cells [8]. Failure in the fusion of the OFT cushions, or if the OFT rotates aberrantly, can result in 
common arterial trunk (CAT) and transposition of the great arteries (TGA), respectively [9]. An 
atrioventricular septal defect (AVSD) can occur if there is an abnormal fusion of the superior and 
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inferior endocardial cushions [10]. The aortic arch arteries are derived from the pharyngeal arch arteries 
(PAAs) that form within the pharyngeal arches from SHF-derived endothelial cells [11]. The pharyngeal 
arches are a transient series of protrusions that develop in a cranial to caudal sequence along the lateral 
surface of the head [12] and are comprised of endoderm, mesoderm, ectoderm, and neural crest cell-
derived mesenchyme [13]. The pharyngeal arches develop by forming pouches from the endoderm that 
meet clefts from the ectoderm to define the boundaries of each arch [14] and the endoderm is considered 
vital for providing cues for this patterning event in a range of species [15–17]. Disruption to pharyngeal 
segmentation is seen when pharyngeal endoderm gene expression is perturbed [15,18–20]. There are five 
bilaterally symmetrical pairs of PAAs that connect the aortic sac to the dorsal aorta. The PAAs then 
asymmetrically remodel to form the left-sided aortic arch and double circulatory system [21] and this 
process is conserved between mice and humans [22]. Aberrant PAA formation and remodelling can result 
in defects such as interruption of the aortic arch type B (IAA-B) [23]. 
The 22q11DS gene Tbx1 is known to interact with many genes in cardiovascular development, 
including Pax9 [24,25] and Gbx2 [24]. Pax9 is specifically expressed in the pharyngeal endoderm at 
embryonic day (E) 9.5 [26], although it is later expressed in the craniofacial region and skeleton. Mice 
deficient for Pax9 die perinatally with a cleft palate, absent pharyngeal-derived glands, skeletal 
abnormalities and have complex heart and aortic arch artery defects [25,27]. Pax9 has been shown to 
functionally interact with Tbx1 in the pharyngeal endoderm for 4th PAA morphogenesis, as double-
heterozygous mice develop IAA-B [25]. Gbx2 has also been implicated in cardiovascular development 
[28,29] and is normally expressed in all three germ layers of the mouse at the early head fold stage 
(E7.5) in a domain that extends rostrally from the posterior end of the embryo, encompassing the 
node, into the prospective hindbrain [30]. In the pharynx, Gbx2 is expressed in the pharyngeal arch 
endoderm and ectoderm at E8.5 [31] but restricted to the pharyngeal endoderm by E9.5 [28]. Gbx2 is 
downregulated in the pharyngeal endoderm of Pax9-null embryos [25] and in the pharyngeal 
endoderm and ectoderm of Tbx1-null embryos [28]. 
In this study, we have examined the cardiovascular phenotype in Gbx2-null mice and identified 
a genetic interaction for cardiovascular development between Gbx2 and Pax9 in complex mutants in 
the pharyngeal endoderm. We also explored a potential genetic interaction between Tbx1, Pax9 and 
Gbx2 for aortic arch artery morphogenesis. 
2. Materials and Methods 
2.1. Mice 
The mice used in this study have previously been described: Gbx2flox [32], Pax9+/− [27], Pax9Cre [25], 
Sox2Cre [33], Tbx1+/− [34], and R26ReYFP [35]. All mice were maintained on a C57Bl/6J genetic 
background. All studies involving animals were performed in accordance with the UK Home Office 
Animals (Scientific Procedures) Act 1986. 
2.2. Breeding 
Male and female mice were mated and the detection of a vaginal plug the next morning 
considered to be embryonic day (E) 0.5. Pregnant females were culled on the required day and 
embryos collected. Embryos at E9.5–E11.5 were staged by somite counting. PCR genotyping primers 
are available on request. 
2.3. Imaging 
Magnetic resonance imaging (MRI), High Resolution Episcopic Microscopy (HREM) and micro-
computed tomography (µCT) techniques were performed as previously described [25,36–39]. 
Volume data sets were segmented using Amira software (ThermoFisher Scientific, Waltham, MA, 
USA) to create 3-dimensional (3-D) images. Structures were manually outlined using the label field 
function of Amira and surface rendered to produce the 3-D images. Intra-cardiac ink injections were 
performed as described [28]. Haematoxylin and eosin staining, immunohistochemistry, and whole-
mount in situ hybridisation, were performed using standard techniques. mRNA expression on 
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sections was examined by in situ hybridisation using RNAscope ® Multiplex Fluorescent v2 Assay 
(Advanced Cell Diagnostics, Newark, CA, USA) following the manufacturer’s instructions. Probe 
and antibody details are given in Table S5. 
2.4. Identifying Conserved Binding Sites in the GBX2 Locus 
Human and mouse genomic GBX2 sequences were aligned in Geneious 10.2.6 
(https://www.geneious.com) using the Align feature, identifying a highly conserved region ~2kb 
downstream from the 2nd and final GBX2 coding exon. This region was scanned for TBX1/5 and 
PAX5/9 consensus binding sequences using the rVista (https://rvista.dcode.org/) and JASPAR 
(http://jaspar.genereg.net/) databases. One TBX5 and three PAX5/9 sites were identified with the 
following sequences: TBX-BE-1, CAGCACCTCA; PAX-BE-1, AGGCAGCCCTTGATG; PAX-BE-2, 
GTCTCAGCTGGCTGATTAA; and PAX-BE-3, TTAATCCAAGGTTGGGTTTTG. 
2.5. Luciferase Assay 
The 500bp Gbx2 conserved region was amplified from mouse genomic DNA by PCR and sub-
cloned into the pGL3-Promoter plasmid (Promega, Madison, WI, USA) downstream of luciferase. 
The cDNAs for PAX9 and TBX1 were cloned into pcDNA3.1. JEG3 cells were seeded at a density of 
1 × 105 cells per well in 24-well plates and transfections were performed in triplicate with jetPRIME 
(Polyplus-transfection, Illkirch, France) using a total of 0.5 µg DNA in a reaction volume of 300 µL. 
Positive control reporter constructs were 2xTkGl2, containing synthetic TBX binding sites [5], and 
p2.4BMP4-luc which binds PAX9 [40]. A renilla luciferase vector (5 ng) was included as a transfection 
control. Wells without DNA or with the empty pcDNA3.1 vector served as negative controls. All 
wells received an equal quantity of DNA per transfection. A dual-luciferase assay (Promega) was 
performed 24 h after transfection. 
2.6. Flow Cytometry 
The pharyngeal arch region of E9.5 Pax9Cre;eYFP control embryos (n = 5; 23–27 somites) was 
dissected from the rest of the embryo and dissociated to single cells with Accumax (ThermoFisher 
Scientific) by incubating at 37 °C for 30 min. The reaction was stopped by the addition of 10% fetal 
calf serum (FCS), the cells washed in PBS, and resuspended in 10% FCS. Cells were stained with 
propidium iodide. Fluorescence-activated cell sorting was performed on a Becton Dickinson FACS 
Aria II using a 100 µm nozzle and a sheath pressure of 20 psi. Single cells were gated using FSC-A vs 
SSC-A followed by FSC-A vs. FSC-H and FSC-A vs SSC-W to remove any doublets. Live single cells 
were gated using propidium iodide vs. FSC-A, and this population finally gated on eYFP-positive 
and -negative cells and sorted into collection tubes. 
2.7. Quantitative Real-Time RT-PCR (qPCR) 
RNA from flow-sorted cells was extracted using Trizol reagent (ThermoFisher Scientific) 
combined with a Purelink RNA Mini Kit (ThermoFisher Scientific) and on-column DNase1 treatment. 
RNA was eluted with 30µl RNase-free water. Total RNA was converted to cDNA using a High-
Capacity cDNA Reverse transcription kit (Applied Biosystems) and random hexamers. qPCR was 
performed using SYBR Green JumpStart Taq ReadyMix (Sigma, St. Louis, MO, USA) using 
previously described Gbx2 and Gapdh primers [25]. All qPCR reactions were performed in triplicate 
on a QuantStudio 7 Real-Time PCR System (ThermoFisher Scientific). Data were analysed using the 
comparative Ct method. 
2.8. Statistical Analysis 
A chi-squared test was used to compare genotype frequencies of litters. Fisher’s exact test and 
Pearson chi-squared test for associations were used to compare defect frequencies between the 
different genotypes (SPSS). qPCR data were tested for variance using the Shapiro–Wilk test (Prism 
8.01 software, GraphPad) and a two-tailed unpaired t-test performed. Luciferase data were analysed 
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using one-way ANOVA with Tukey’s multiple comparison test (Prism 8.01 software, GraphPad). 
Groups were considered significantly different when p < 0.05. 
3. Results 
3.1. Gbx2 Expression in the Pharyngeal Endoderm 
Coordinated gene expression in the pharyngeal arches is a prerequisite for the correct 
development of the PAA. We confirmed the expression of Gbx2, Pax9 and Tbx1 in mid-embryogenesis 
mouse embryos. At E8.5, Gbx2 and Pax9 are expressed in the pharyngeal region of the mouse embryo, 
with Gbx2 also expressed at the mid-hindbrain boundary (Figure 1A,B) [27,28,41]. At E9.5, Gbx2 and 
Pax9 are co-expressed in the pharyngeal endoderm (Figure 1C), as are Pax9 and Tbx1 (Figure 1D) [25]. 
Gbx2, Pax9 and Tbx1 expression are maintained in the pharyngeal endoderm at E10.5 (Figure 1E,F). 
Analysis of Pax9Cre activated eYFP positive cells [25] by qPCR from E9.5 embryos confirmed that 
Gbx2 expression is enriched in the pharyngeal endoderm compared to the remaining pharyngeal arch 
tissues (Figure 1G). Gbx2 expression is bilaterally reduced in the pharyngeal endoderm of Pax9-null 
embryos at E9.5 as shown by whole-mount in situ hybridisation (Figure 1H–K) [25]. 
 
Figure 1. Gbx2 and Pax9 expression in the pharyngeal endoderm. (A–F) RNA in situ hybridisation 
was used to visualise transcripts in the normal developing embryo. At E8.5 whole embryo in situ 
hybridisation reveals Pax9 (A) and Gbx2 (B) expression in the pharyngeal pouch (pp) region. Gbx2 is 
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also expressed in the mid-hindbrain (mhb) (n = 3 embryos per probe, 9–11 somites). (C–F) RNAScope 
probes were used on sections at E9.5 (n = 3, 24–28 somites) and E10.5 (n = 3, 33 somites). At E9.5 Pax9 
and Gbx2 (C), and Pax9 and Tbx1 (D) co-localise to the pharyngeal endoderm. At E10.5 Pax9 (E), Gbx2 
(E’) and Tbx1 (F), are all expressed in the pharyngeal endoderm. (G) qPCR on flow-sorted cells from 
Pax9Cre;eYFP E9.5 embryos (n = 5, 23–27 somites) shows a significant enrichment for Gbx2 in the eYFP-
positive cells compared to eYFP-negative. *p < 0.05; two-tailed unpaired t-test. (H,J) Whole embryo 
in situ hybridisation at E9.5 in wild-type (H; n = 3, 24–26 somites) and Pax9−/− (J; n = 6, 23–27 somites) 
embryos. Gbx2 expression is reduced in the pharyngeal pouch in Pax9−/− embryos. (I,K) Sections of 
stained embryos revealed reduced Gbx2 staining in the pharyngeal endoderm in Pax9−/− embryos (K) 
compared to controls (I). (L) Diagram of the GBX2 locus showing the degree of conservation (%) 
between human and mouse GBX2 sequences. A 500bp region, ~2kb down from the second, and final, 
GBX2 coding exon is 99% conserved and contains PAX (blue) and TBX (red) binding elements (BE). 
(M–O) Luciferase assays show that Pax9 activates the Gbx2 conserved region but Tbx1 does not (O). 
Controls for Tbx1 (M) and Pax9 (N) show significant activation of luciferase. Data presented as the 
mean ± s.e.m. of 6 individual experiments, each performed in triplicate. *p < 0.05, ***p < 0.01, ****p < 
0.001. Scale bars: 100 µm in A, B, H and J; 50 µm in C-F, H’, I, J’ and K. Abbreviations: me, mesoderm; 
pa, pharyngeal arch; pe, pharyngeal endoderm; s, somites. The somite numbers given in the legend 
reflect the range analysed for the whole study. The figure contains representative images only. 
We have previously identified Gbx2 as a potential target gene of Pax9 [25]. To examine the Gbx2 
locus for potential regulatory elements we aligned the mouse and human sequences and found a 
500bp region with 99% homology (Figure 1L). This region, located ~2kb downstream of the second 
and final Gbx2 coding exon, contains a previously reported TBX binding site [42]. Scanning this region 
identified the known TBX site as well as three potential PAX binding sites. This 500bp conserved 
region was sub-cloned into a luciferase plasmid and transfected into JEG3 cells with PAX9 and TBX1 
expression plasmids. Dual-luciferase assays showed a significant upregulation of luciferase in the 
presence of the PAX9 expression plasmid, but no effect was seen with TBX1 (Figure 1O). Co-
transfection of PAX9 with TBX1 resulted in no increase in luciferase compared to the control 
suggesting that TBX1 might be repressing the effect of PAX9 on the Gbx2 conserved region. This data 
implies that PAX9 and TBX1 may interact with a potential GBX2 enhancer to regulate the expression 
of GBX2, and this interaction is likely to occur in the pharyngeal endoderm where all three genes are 
expressed from E9.5. 
3.2. Gbx2-Null Cardiovascular Defects 
As Gbx2 was significantly down-regulated in Pax9−/− embryos [25], and PAX9 was able to activate 
a conserved region of the Gbx2 locus, we asked whether these two genes genetically interacted in 
vivo. Gbx2−/− mice have previously been shown to have cardiovascular defects at foetal and embryonic 
stages [28,29]. To confirm these observations we created a null allele of Gbx2 by crossing Gbx2flox mice 
[32] with Sox2Cre mice [33], which drives Cre-mediated recombination in all embryonic tissues by 
gastrulation. Gbx2flox;Sox2Cre mice, carrying the recombined Gbx2-null allele, hereafter referred to as 
the Gbx2– allele, were subsequently crossed with wild-type mice to breed out the Sox2Cre allele and 
to propagate the Gbx2– allele through the germline. Heterozygous Gbx2+/− mice were intercrossed to 
generate Gbx2−/− embryos for analysis of cardiovascular developmental defects. Slide in situ 
hybridisation on E9.5 embryo sections demonstrated complete loss of Gbx2 RNA in Gbx2−/− embryos 
(Figure S1). Genotype analysis of embryos and neonates (E8.5 to P0) indicated there was a statistically 
significant reduction in the expected number of Gbx2−/− offspring observed (Table S1) despite no 
evidence of an excessive number of resorptions. 
Analysis of Gbx2−/− embryos at E15.5 by magnetic resonance imaging (MRI) revealed that 64% (n 
= 16/25) had some form of cardiovascular developmental defect including aberrant right subclavian 
artery (A-RSA), right-sided aortic arch (RAA), right-sided arterial duct (RAD) and double-outlet right 
ventricle (DORV) (Figure 2A–C; Table 1), although interruption of the aortic arch (IAA) was not 
observed. Of these Gbx2−/− embryos with cardiovascular defects, 56% (n = 9/16) displayed additional 
overt left-right patterning defects such as right pulmonary isomerism, bilateral superior caval veins 
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draining into a common right atrium (i.e., right atrial isomerism), and mirror-image aortic arch 
arteries (Figure 2D–H; Table 1). An enlargement of the right dorsal aorta, compared to the left, was 
also noted in two Gbx2−/− embryos analysed by high-resolution episcopic microscopy (HREM), 
indicating that these embryos would have developed an aberrant right-sided dorsal aorta by the 
foetal stage (Figure 2O,P). A left-right patterning phenotype in Gbx2−/− mice has not previously been 
reported. Left-right patterning is established via a Nodal-Pitx2c gene regulated pathway [43] and to 
investigate whether the left-right patterning defect was due to altered Pitx2c expression, whole-
mount in situ hybridisation was performed on Gbx2−/− embryos at E8.5 (n = 6). No obvious change in 
Pitx2c expression, however, was observed in the left lateral plate mesoderm (Figure 2I,J). 
Table 1. Number of cardiovascular defects observed in Gbx2;Pax9 mutant mice. 
Genotype n Abnormal VSD AVSD 
DORV + 
IVC 
CAT 
RAA/RAD 
+/or A-SA a 
IAA-B +/- 
A-RSA 
Absent  
CC b 
L-R 
defect c 
Gbx2−/− 25 
16 
(64%) 
2 
(8%) 
0 10 (40%) 0 
13 
(52%) 
0 0 
9 
(36%) 
Gbx2+/−; 
Pax9+/− 
28 
6 
(21%) 
0 0 0 0 
4 
(14%) 
2 
(7%) 
0 0 
Gbx2−/−; 
Pax9+/− 
14 
14 
(100%)* 
3 
(21%) 
0 
7 
(50%) 
1 
(7%) 
8 
(57%) 
5** 
(36%) 
2 
(16%) 
6 
(43%) 
Pax9−/− 9 
9 
(100%) 
2 
(22%) 
0 
3 
(44%) 
0 0 
8 
(89%) 
5 
(56%) 
0 
Gbx2+/−; 
Pax9−/− 
9 
9 
(100%) 
2 
(22%) 
0 
5 
(56%) 
2 
(22%) 
1 
(11%) 
8 
(89%) 
6 
(67%) 
0 
Gbx2−/−; 
Pax9−/− 
2 
2 
(100%) 
0 
1 
(50%) 
0 
1 
(50%) 
1 
(50%) 
1 
(50%) 
1 
(50%) 
0 
Gbx2−/flox; 
Pax9Cre 
14 
3 
(21%) 
0 0 0 0 
3 
(21%) 
0 
1 
(7%) 
0 
Embryos and neonates were collected from Gbx2+/−;Pax9+/− and Gbx2flox;Pax9Cre crosses. All embryos 
were analysed at E13.5-E15.5 by MRI, µCT and histology. Neonates were analysed by dissection at 
P0: Gbx2+/−;Pax9+/− (n = 12), Gbx2−/−; Pax9+/− (n = 1), Pax9−/− (n = 2), Gbx2+/−;Pax9−/− (n = 2), and Gbx2−/−;Pax9−/− 
(n = 1). Results for embryos and neonates are combined. The outflow tract phenotype was not assessed 
in neonates. All wild-type (n = 12), Pax9+/− (n = 8), Gbx2+/− (n = 22), Gbx2+/flox (n = 6), Gbx2−/flox (n = 9) and 
Pax9Cre (n = 12) control embryos and neonates assessed were normal. There was a statistically 
significant increase in the incidence of cardiovascular defects in total, and IAA-B specifically, in 
Gbx2−/−;Pax9+/− embryos compared to the Gbx2−/− embryos. *p < 0.05, **p = 0.01 (Fisher’s exact test). a A-
SA refers to a right or left retro-esophageal subclavian artery, cervical origin of the RSA, or an isolated 
RSA. One Pax9−/−, three Gbx2−/− and both Gbx2−/−; Pax9−/− embryos had isolated RSA. b Absent common 
carotid artery (CC), resulting in the internal and external carotid arteries arising directly from the 
main aortic vessels, unilaterally or bilaterally. c L-R defect refers to an overt left-right patterning defect 
where embryos show either right pulmonary isomerism, right atrial isomerism or mirror image 
branching of the aortic arch arteries. Abbreviations: AoA, aortic arch; A-RSA, aberrant right 
subclavian artery; A-SA, aberrant subclavian artery (left or right); AVSD, atrioventricular septal 
defect; DORV + IVC, double outlet right ventricle with interventricular communication; IAA-B, 
interruption of the aortic arch, type B; RAA, right-sided aortic arch; RAD, right-sided arterial duct; 
RSA, right subclavian artery; VSD, perimembranous ventricular septal defect. 
Analysis of Gbx2−/− embryos at E10.5 by intracardiac ink injection and HREM demonstrated that 
the 4th PAA was affected in 71% (n = 12/17) of embryos, being either absent or hypoplastic (Figure 
2K–P; Table 2). Ink injection of Gbx2+/− embryos at E10.5 revealed a low level of unilateral 4th PAA 
defects (Table 2). Embryos at E11.5 also showed PAA defects by HREM including absent and 
hypoplastic 4th PAAs as well as delayed septation of the OFT compared to stage-matched controls 
(Figure 2Q–S). Immunohistochemical staining for ERG1 showed that the endothelium within the 3rd 
and 4th pharyngeal arches had formed lumenised PAAs at E10.5 in control embryos (Figure 2T), but 
in Gbx2−/− embryos a visibly reduced number of endothelial cells around the 4th PAA, or only isolated 
endothelial cells present within the 4th pharyngeal arch, were observed (Figure 2U,V). 
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Table 2. Number of pharyngeal arch artery defects observed in Gbx2;Pax9 mutant embryos. 
 Bilateral Defects 
Genotype n PAA 
Abnormal 
(%) 
Unilateral 
Defect 
Bilateral 
Defect 
Present 
Hypo/Int/
Abs 
Absent 
Gbx2+/− 44 4 3 (7%) 3 (7%) 0 - - - 
Gbx2+/−; 
Pax9+/− 
63 4 20 (32%) 13 (21%) 7 (11%) - 3 4 
Gbx2−/− 17 4 12 (71%) 7 (41%) 5 (29%) - 3 2 
Gbx2−/−; 
Pax9+/− 
7 4 7 (100%) 1 (14%) 6 (86%)* - 2 4 
Pax9−/− a 22 
1 13 (59%) 1 (5%) 12 (55%) 11 1 - 
2 8 (36%) 3 (14%) 5 (23%) 4 1 - 
3 17 (77%) 3 (14%) 14 (64%) - 10 4 
4 22 (100%) 1 (5%) 21 (95%) - 3 18 
Gbx2+/−; 
Pax9−/− 
6 
1 6 (100%) 0 6 (100%) 6 - - 
2 2 (33%) 2 (33%) 0 - - - 
3 6 (100%) 0 6 (100%) - 1 5 
4 6 (100%) 0 6 (100%) - - 6 
Gbx2−/−; 
Pax9−/− 
1 4 1 (100%) 0 1 (100%) - - 1 
Gbx2+/flox; 
Pax9Cre 
19 4 2 (10%) 1 (5%) 1 (5%) - - 1 
Gbx−2/flox; 
Pax9Cre 
14 4 7 (50%)* 5 (36%) 2 (14%) - 1 1 
Embryos were collected from Gbx2+/−;Pax9+/− and Gbx2flox;Pax9Cre crosses and assessed for PAA defects 
by intracardiac ink injections. Gbx2−/− embryos were also imaged using HREM (E10.5, n = 3 and E11.5, 
n = 5) to visualise the PAA. Data are combined. For Pax9−/− and Gbx2+/−;Pax9−/− genotypes each left and 
right PAA 1–4 was scored as having a unilateral or bilateral defect, and the bilateral defects 
categorised as either present, a combination of hypoplastic, interrupted and/or absent 
(Hypo/Int/Abs), and bilaterally absent. For all other genotypes ink injection was performed at E10.5 
and only the 4th PAA was scored. All control embryos, Pax9+/− (n = 18), Gbx2+/flox (n = 22) and Gbx2−/flox 
(n = 15) were normal. There was a significantly increased incidence of bilateral 4th PAA defects in 
Gbx2−/−; Pax9+/− embryos compared to Gbx2−/− embryos, and abnormal 4th PAA defects in Gbx2−/flox; 
Pax9Cre embryos compared to Gbx2+/flox; Pax9Cre embryos. *p < 0.05 (Pearson’s Chi-square test for 
associations). a New data (n = 2) combined with published data (n = 20) [25]. 
All mice deficient for Gbx2 die perinatally, and a high proportion of these are with 
cardiovascular abnormalities affecting the outflow tract and/or the 4th PAA-derived arteries. In 
contrast to previously published data, where 50% of Gbx2-null embryos had a PAA phenotype and 
39% of foetuses had a cardiovascular defect [28,29], we observed a higher penetrance of 
cardiovascular abnormalities at embryonic (71%) and foetal (64%) stages. Our Gbx2-null embryos did 
not present with IAA as previously described [29]. Gbx2 has been postulated to be a downstream 
target of Pax9 [25], and here we also demonstrate that a conserved region in the Gbx2 locus is activated 
by PAX9. 
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Figure 2. Cardiovascular defects in Gbx2−/− embryos. (A–H) 3D reconstructions from MRI datasets of 
E15.5 embryos. (A) Gbx2+/+ control embryo with normal heart and aortic arch arteries. (B,C) In Gbx2−/− 
embryos (n = 25), defects seen include double outlet right ventricle (DORV) with interventricular 
communication (IVC), retro-oesophageal aberrant right subclavian artery (A-RSA), isolated RSA (I-
RSA) and right-sided arterial duct (RAD). (D–H) Left-right patterning defects were observed in a 
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subset of Gbx2−/− embryos (n = 9/25). (D) Normal lungs from a control embryo showing cranial (Cr), 
middle (Mi), caudal (Ca) and accessory (Ac) lobes of the right lung, and a single lobed left lung (LL). 
(E) Gbx2−/− embryo with right pulmonary isomerism. (F) Gbx2−/− embryo heart with mirror image 
arrangement of the arch arteries and the ventricles, DORV and an aberrant left subclavian artery (A-
LSA). (G,H) Dorsal view of the heart and the caval veins. (G) Control embryo showing the right 
superior caval vein (RSCV) and inferior caval vein (ICV) draining directly into the right atrium (RA) 
and the left SCV (LSVC) draining into the RA via the coronary sinus (CS). (H) Gbx2−/− embryo with 
the right and left SCVs, and the paired ICV, draining directly into a common atrium (right atrial 
isomerism). (I, J) Whole-mount in situ hybridisation with a Pitx2 riboprobe. Pitx2 isoforms were seen 
in the head mesoderm (HM) and left lateral plate mesoderm (LLPM) of control (n = 3) and Gbx2−/− (n 
= 6) embryos. All embryos were between 9–11 somites. (K–M) Intracardiac ink injection into E10.5 
embryos (34–38 somites). (K) In control embryos (n = 18), PAAs 3–6 are patent to ink, are of equivalent 
diameter and are bilaterally symmetrical. (L,M) In Gbx2−/− embryos (n = 17), the 4th PAAs are 
frequently hypoplastic (L) or non-patent to ink (M; asterisk). (N–S) Embryos were examined by high-
resolution episcopic microscopy at E10.5 (34–35 somites; N–P) and E11.5 (45–47 somites; Q–S). 
Coronal views are shown. (N) In control E10.5 embryos (n = 5), the 3rd, 4th, and 6th PAAs, and the 
left and right dorsal aortae (L/RdAo), are of equal size and bilaterally symmetrical. (O,P) In Gbx2−/− 
embryos (n = 3), the 4th PAAs were either absent (O; asterisk), or hypoplastic (O,P). The left dorsal 
aorta was seen to be abnormally thinner than the right (O,P). (Q) In control embryos at E11.5 (n = 3), 
the outflow tract is septated into the aorta (A) and pulmonary trunk (pt), and the right 6th PAA has 
thinned. (R, S) In Gbx2−/− embryos (n = 5), the 4th PAAs are frequently unilaterally absent (asterisk). 
Septation of the aortic sac (as) is delayed. (T–V) Immunostaining using anti-ERG1 antibody at E10.5 
(34–36 somites). (T) Control embryos (n = 3) have a ring of ERG1-positive endothelium lining the 3rd 
and 4th PAAs (white arrowheads). (U,V) In Gbx2−/− embryos (n = 4), the 4th PAAs appeared to have 
abnormal endothelial cells (U), or disorganized endothelial cells within the 4th pharyngeal arch in the 
absence of a PAA (V; yellow arrowheads). Scale bars: 500 µm in A–H; 100 µm in I–S; 50 µm in T–V. 
Abbreviations: Ao, aorta; AD, arterial duct; LCC, left common carotid artery; LSA, left subclavian 
artery; LV, left ventricle; pa, pharyngeal arch; RCC, right common carotid artery; RSA, right 
subclavian artery; RV, right ventricle; s, somites. The somite numbers given in the legend reflect the 
range analysed for the whole study. The figure contains representative images only. 
3.3. Genetic Interaction between Gbx2 and Pax9 
To investigate a genetic interaction in vivo, mice heterozygous for Pax9 and Gbx2, which are 
viable and fertile with no observed developmental defects, were intercrossed to produce 
Gbx2+/−;Pax9+/− mice and embryos for analysis. Gbx2+/−;Pax9+/− mice were observed to survive to 
weaning albeit at a significantly lower than expected number (p < 0.05; Table S2). To investigate any 
perinatal lethality to explain the loss of Gbx2+/−;Pax9+/− mice, neonates were observed from the day of 
birth. Four pups were recovered which had died on the first post-natal day, all of which were 
Gbx2+/−;Pax9+/−, and showed a cardiovascular defect when dissected including RAA, IAA-B and A-
RSA (Figure 3A–C; Table 1). Surviving littermates were culled and a further eight Gbx2+/−;Pax9+/− 
neonates were identified which showed no cardiovascular defects. All wild type (n = 8), Gbx2+/− (n = 
10) and Pax9+/− (n = 9) littermates were normal. To further investigate the Gbx2+/−;Pax9+/− cardiovascular 
phenotype, embryos were collected at E15.5 and analysed by histology. From 16 Gbx2+/−;Pax9+/− 
embryos collected, two had a defect affecting the arch arteries including RAA and A-RSA (Figure 
3D–I) and RAD (Table 1). Embryos were collected at E10.5 to analyse the forming PAA by ink 
injection. This revealed that 30% (n = 19/63) of Gbx2+/−;Pax9+/− mutants had a defect where the 4th PAA 
was either hypoplastic or absent in affected embryos (Figure 3J–L; Table 2). 
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Figure 3. Cardiovascular defects in Gbx2+/−;Pax9+/− mice. (A–C) Neonates were dissected on the day of 
birth. (A) Arch arteries of control neonates were normal. (B) A subset of Gbx2+/−;Pax9+/− neonates (4/12) 
displayed right-sided aortic arch (RAA; B) or IAA-B (C). (D–I) H&E stained transverse sections of 
E15.5 embryos. (D–F) Normal outflow tract (D), aortic arch arteries and thymus (Th; E,F) in a control 
embryo. (G–I) A Gbx2+/−;Pax9+/− embryo (from n = 16) with aberrant right subclavian artery (A-RSA; 
G), a right-sided aortic arch (RAA; H) and abnormal thymus (H,I). (J–L) Intracardiac ink injection into 
E10.5 embryos (34–41 somites). (J) In control embryos, PAAs 3–6 are patent to ink, are of equivalent 
diameter and are bilaterally symmetrical. (K,L) In Gbx2+/−;Pax9+/− embryos (n = 63), 32% had 
hypoplastic (K) or non-patent to ink (L; asterisk) 4th PAAs. Scale bars: 1 mm in A–C; 500 µm in D–L. 
Abbreviations: AD, arterial duct; Ao, aorta; AoA, aortic arch; LCC, left common carotid artery; LSA, 
left subclavian artery; PT, pulmonary trunk; RCC, right common carotid artery; RSA, right subclavian 
artery; s, somites. The somite numbers given in the legend reflect the range analysed for the whole 
study. The figure contains representative images only. 
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Our data therefore indicates that there is a genetic interaction occurring between Gbx2 and Pax9, 
albeit at a low incidence, where biallelic expression of both genes is required for cardiovascular 
development to proceed normally. There was a loss in the expected number of double heterozygous 
mice at weaning and an observable aortic arch artery phenotype in a subset of embryos and neonates, 
including IAA-B which was not seen in Gbx2−/− mice in this study (Table 1). 
To see if a further reduction in Gbx2 and Pax9 alleles would result in a more penetrant 
cardiovascular phenotype, Gbx2+/−;Pax9+/− mice were intercrossed and embryos and neonates collected 
for analysis. Genotyping revealed that all mice null for Gbx2 were under-represented (p = 1.12 × 10−4; 
Table S3). We first analysed mutant mice null for Gbx2 and simultaneously heterozygous for Pax9 
(i.e., Gbx2−/−;Pax9+/−). One Gbx2−/−;Pax9+/− neonate was recovered that died on the day of birth with IAA-
B, A-RSA, and an absent left common carotid artery resulting in the left internal and external carotid 
arteries arising from the aortic arch and dorsal aorta as previously described in Pax9−/− embryos [25] 
(Figure 4A,B). Gbx2−/−;Pax9+/− embryos at E13.5 and E15.5 were examined for cardiovascular defects 
by histology and MRI respectively, which showed a significantly increased penetrance of OFT and 
arch artery defects compared to those observed in Gbx2−/− mice (100% versus 64%, p < 0.05; Figure 4C–
M; Table 1). There was also a significant increase in the presentation of IAA-B in Gbx2−/−;Pax9+/− mice 
compared to Gbx2−/− mice (36% versus 0, p < 0.01; Figure 4B,E; Table 1), a defect not observed in our 
Gbx2−/− or Pax9+/− mice. We also observed a partial CAT (type A4 where the common trunk is 
associated with IAA [44]) in one Gbx2−/−;Pax9+/− embryo (Figure 4G), a phenotype not previously 
described in Gbx2-null and Pax9-null embryos [25,28,29]. Analysis of the PAA at E10.5 by ink injection 
revealed that all Gbx2−/−;Pax9+/− embryos had an affected 4th PAA, with a significantly higher 
incidence of bilateral 4th PAA defects compared to Gbx2−/− embryos (p < 0.05; Figure 4N–Q; Table 2). 
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Figure 4. Cardiovascular defects in Gbx2−/−;Pax9+/− mice. (A–B) Neonates were dissected on the day of 
birth. (A) Arch arteries of control neonates were normal. (B) One Gbx2−/−;Pax9+/− neonate found dead 
on the day of birth displayed IAA-B and an aberrant left and right internal and external carotid artery 
(iLC, eLC, iRC, eRC). (C–H) H&E stained transverse sections of E13.5 embryos (n = 5). A normal 
outflow tract (C), aortic arch (Ao) and thymus (Th; D) are seen in control embryos. In two 
Gbx2−/−;Pax9+/− mutant embryos (E, F and G, H) the defects include IAA-B (E), an aberrant right internal 
carotid artery (iRC; F), and a partial common arterial trunk (pCAT) emerging from the left ventricle 
(G). The pulmonary trunk is right-sided (R-PT; H) and the aorta was interrupted (not shown). The 
thymus is absent in both mutants (F,H). (J–M) 3D reconstructions of MRI datasets of hearts from a 
normal control embryo (J) and Gbx2−/−;Pax9+/− mutant embryos (n = 8). Defects include aberrant right 
subclavian artery (A-RSA; K,L), double outlet right ventricle (DORV; K,M), right-sided aortic arch 
(RAA; L,M). Situs patterning defects were also observed, including mirror image aortic arch arteries 
(RAA, RAD, RdAo) with aberrant left subclavian artery (A-LSA) and aberrantly positioned ventricles 
(M). (N–Q) Intracardiac ink injection into E10.5 embryos (35–39 somites). (N) In control embryos, 
PAAs 3–6 are patent to ink. (K, L) In Gbx2+/−;Pax9+/− embryos (n = 7), all had an aberrant 4th PAA 
including hypoplastic (O) or non-patent to ink (P,Q; asterisk) vessels. Scale bars: 1 mm in A–B; 500 
µm in C–Q. Abbreviations: Ao, aorta; AD, arterial duct; dAo, dorsal aorta; LCC, left common carotid 
artery; LSA, left subclavian artery; LV, left ventricle; PT, pulmonary trunk; RCC, right common 
carotid artery; RSA, right subclavian artery; RV, right ventricle; s, somites. The somite numbers given 
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in the legend reflect the range analysed for the whole study. The figure contains representative images 
only. 
As Pax9 heterozygosity modified the Gbx2−/− phenotype we next looked to see if Gbx2 
heterozygosity modified the Pax9−/− phenotype. Gbx2+/−;Pax9−/− embryos examined at E15.5 and E10.5 
presented with the typical Pax9-null cardiovascular phenotype (Figure 5) and no left-right patterning 
defects were seen. Two cases of type A4 partial CAT, however, were observed (Figure 5I; Table 1). At 
E10.5 there was an insignificant increase in the penetrance of 1st and 3rd PAA defects in the 
Gbx2+/−;Pax9−/− embryos (Figure 5L; Table 2). 
 
Figure 5. Cardiovascular defects in Gbx2+/−;Pax9−/− mice. (A–C) Neonates were dissected on the day of 
birth. (A) Arch arteries of control neonates were normal. (B) Pax9−/− (n = 2) and (C) Gbx2−/−;Pax9+/− (n = 
2) neonates found dead on the day of birth displayed interruption of the aortic arch (IAA-B) and 
presumed aberrant right subclavian artery. (D–F) 3D reconstructions of E15.5 hearts from MRI 
datasets. (D) Gbx2+/+ control embryo with normal heart and aortic arch arteries. (E) Pax9−/− embryos (n 
= 7) presented with defects such as IAA-B, A-RSA, double outlet right ventricle (DORV), hypoplastic 
aorta and aberrant carotid arteries (eRCA, iRCA). (F) Gbx2+/−;Pax9−/− embryos (n = 7) showed typical 
Pax9−/− cardiovascular defects including IAA-B and absent common carotid artery, but also common 
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arterial trunk (CAT). (G–I) E15.5 embryos were sectioned and stained with H&E. (G) Control embryos 
had a normal outflow tract. (H) Pax9−/− embryos had DORV (not shown) and hypolastic aorta. (I) 
Gbx2+/−;Pax9−/− embryo with CAT. (J–L) Embryos at E10.5 were analysed by intracardiac ink injection 
(35–38 somites). (J) Control embryos had normal PAAs patent to ink. (K) Pax9−/− embryos showed 
typical defects such as persistent 1st, hypoplastic 3rd and absent 4th PAAs (asterisk), as did 
Gbx2+/−;Pax9−/− embryos (n = 6; L). Scale bars: 1 mm in A–C; 500 µm in D–L. Abbreviations: Ao, aorta; 
AD, arterial duct; LCC, left common carotid artery; LSA, left subclavian artery; LV, left ventricle; PA, 
pulmonary artery; PT, pulmonary trunk; RCC, right common carotid artery; RSA, right subclavian 
artery; RV, right ventricle; s, somites. The somite numbers given in the legend reflect the range 
analysed for the whole study. The figure contains representative images only. 
From the Gbx2+/−;Pax9+/− intercross only three Gbx2−/−;Pax9−/− mice were recovered from a total of 
172 offspring, one each at P0, E15.5 and E10.5, and these mice displayed the typical Pax9−/− 
phenotypes, as well as AVSD and full CAT (with an isolated right subclavian artery), both of which 
are defects not previously seen in either Gbx2−/− or Pax9−/− embryos (Figure 6; Tables 1 and 2). 
 
Figure 6. Cardiovascular defects in the three Gbx2−/−;Pax9−/− mutants recovered. (A–D) Neonates were 
dissected on the day of birth. The thymus (A) and arch arteries (B) were normal in controls, but in a 
Gbx2−/−;Pax9−/− neonate the thymus was absent (asterisk; C) and the arch arteries were abnormal (D) 
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displaying interrupted aortic arch type B (IAA-B), isolated right subclavian artery (I-RSA) and 
abnormal left carotid arteries (eLCA, iLCA). (E,F) 3D reconstructions of E15.5 hearts from MRI 
datasets. (E) Control embryo with normal heart and aortic arch arteries. (F) Gbx2−/−;Pax9−/− embryo 
with IAA-B, I-RSA, common arterial trunk (CAT) with interventricular communication (IVC), and 
aberrant carotid arteries (eLCA, iLCA, eRCA, iRCA). (G,H) Embryos at E10.5 were analysed by 
intracardiac ink injection. (G) Control embryos had normal PAAs patent to ink. (H) Gbx2−/−;Pax9−/− 
embryo with a non-patent 4th PAA (asterisk). (I–P) H&E stained transverse sections of E15.5 embryos. 
(I–L) Control embryo with normal heart (I), outflow tract (J), aortic arch arteries (K,L) and thymus 
(Th; L). (M–P) Sections from the Gbx2−/−;Pax9−/− embryo depicted in F. (M) An atrioventricular septal 
defect (AVSD) is seen, as well as the CAT (N) with associated I-RSA (O) and aberrant carotid arteries 
(P). Scale bars: 500 µm. Abbreviations: AD, arterial duct; Ao, aorta; AoA, aortic arch; dAo, dorsal 
aorta; LA, left atrium; LCC, left common carotid artery; LSA, left subclavian artery; LV, left ventricle; 
RA, right atrium; RCC, right common carotid artery; RSA, right subclavian artery; RV, right ventricle. 
The thymus is always absent in Pax9−/− embryos [25], yet usually unaffected in Gbx2−/− embryos 
(Figure S2; Table S4). In 70% of Gbx2−/−;Pax9+/− embryos the thymus was abnormal or absent. The 
palate, however, was only affected in mice with Pax9−/− genotypes (Figure S2). 
It appears, therefore, that creating complex alleles of Gbx2 and Pax9 reveals evidence of a genetic 
interaction occurring between these two genes as cardiovascular defects are seen in double 
heterozygous embryos. Furthermore, by creating more complex Gbx2;Pax9 alleles such as Pax9 
heterozygosity with the Gbx2−/− genotype and Gbx2 heterozygosity with the Pax9−/− genotype, not only 
are Pax9-null type defects such as IAA-B and absent common carotid arteries introduced, but also a 
CAT phenotype not seen in either single Gbx2−/− or Pax9−/− embryos is observed. 
3.4. Gbx2 and Pax9 Interact in the Pharyngeal Endoderm for Cardiovascular Development 
To further investigate the site of this genetic interaction we utilised our Pax9Cre mouse line, 
where the Pax9Cre allele corresponds to a Pax9-null allele [25], to conditionally recombine the Gbx2flox 
allele specifically in the pharyngeal endoderm (Figure S3). Embryos conditionally deleted for Gbx2 
using Pax9Cre (i.e., Gbx2−/flox;Pax9Cre) lost the majority of Gbx2 mRNA expression from the pharyngeal 
endoderm at E9.5 (Figure 7B). Embryos at E10.5 were examined by ink injection to assess the PAAs. 
Whereas only 10% (2/19) of embryos double heterozygous for Gbx2 in the pharyngeal endoderm (i.e., 
Gbx2+/flox;Pax9Cre) had an abnormal 4th PAA (Table 2), there was a significant increase in the 
penetrance of 4th PAA defects (7/14; p < 0.05) in the embryos null for Gbx2 in the pharyngeal 
endoderm (i.e., Gbx2−/flox;Pax9Cre) (Figure 7D; Table 2). Examining Gbx2−/flox;Pax9Cre mutant mice at 
E15.5 by MRI revealed cardiovascular defects including RAA, A-RSA and absent common carotid 
arteries in 3/14 embryos analysed (Figure 7F; Table 1). Despite a relatively low incidence of 
cardiovascular defects in embryos with a conditional Pax9Cre driven deletion of Gbx2, this data 
collectively demonstrates that a genetic interaction between Gbx2 and Pax9 is taking place in the 
pharyngeal endoderm. 
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Figure 7. Conditional deletion of Gbx2 from the pharyngeal endoderm. Embryos with one Gbx2-null 
allele and a heterozygous conditional deletion of Gbx2 using Pax9Cre (Gbx2−/flox;Pax9Cre) were 
analysed. (A, B) RNAscope in situ hybridisation for Gbx2 at E9.5 (n = 5 per genotype; 24–29 somites). 
(A) In control embryos Gbx2 expression was observed in the pharyngeal endoderm (pe) of the 
pharyngeal arches (pa). (B) Gbx2 expression was reduced in the pharyngeal endoderm of 
Gbx2−/flox;Pax9Cre mutants. (C,D) Embryos at E10.5 were analysed by intracardiac ink injection (36–38 
somites). (C) Control embryos had normal PAAs patent to ink. (D) Gbx2−/flox;Pax9Cre embryos (n = 14) 
showed PAA defects such as absent 4th PAAs (asterisk). (E,F) 3D reconstructions of E15.5 hearts from 
MRI datasets. (E) Control embryo with normal heart and aortic arch arteries. (F) A Gbx2−/flox;Pax9Cre 
embryo (from n = 14 analysed) with double-outlet right ventricle (DORV), right-sided aortic arch 
(RAA), aberrant right subclavian artery (A-RSA) and abnormal left external and internal carotid 
arteries (eLCA, iLCA). Scale bars: 50µm in A,B; 100µm in C,D; 500µm in E,F. Abbreviations: Ao, aorta; 
AD, arterial duct; LCC, left common carotid artery; LSA, left subclavian artery; LV, left ventricle; RCC, 
right common carotid artery; RSA, right subclavian artery; RV, right ventricle; s, somite. The somite 
numbers given in the legend reflect the range analysed for the whole study. The figure contains 
representative images only. 
3.5. Exploring a Genetic Interaction between Gbx2, Pax9 and Tbx1 
Tbx1 has been shown to genetically interact with Gbx2 and Pax9 in the pharyngeal ectoderm and 
endoderm respectively [25,28]. Our and published data [42] also show that Pax9 and Tbx1 occupy the 
same conserved region in the Gbx2 locus (Figure 1) and Tbx1, Pax9 and Gbx2 are co-expressed in the 
pharyngeal endoderm at E9.5 and E10.5 (Figure 1C–F) [25,28]. Pax9 and Gbx2, and Tbx1 and Gbx2, 
are downregulated in the pharyngeal endoderm of Tbx1−/− and Pax9−/− mice respectively (Figure 8A–
L) [24,25] but Pax9 and Tbx1 expression were maintained in the pharyngeal endoderm of Gbx2−/− 
embryos at E9.5 (Figure 8D,H). We nevertheless speculated that a gene regulatory network may be 
occurring in the pharyngeal endoderm involving Gbx2, Pax9 and Tbx1. To investigate this we 
analysed Gbx2+/−;Pax9+/−;Tbx1+/− triple heterozygous embryos at E15.5-E16.5 by µCT imaging and 
compared the observed cardiovascular defects with double heterozygous Tbx1+/−;Pax9+/− and 
Tbx1+/−;Gbx2+/− embryos (Figure 8M–R; Table 3). Although a non-significant reduction in the 
penetrance of 4th PAA derived defects was seen in Tbx1+/−;Gbx2+/− embryos compared to Tbx1+/− 
embryos, a similar number and type of cardiovascular defect was observed between Tbx1+/−;Pax9+/− 
double heterozygous and Tbx1+/−;Gbx2+/−;Pax9+/− triple heterozygous embryos (Figure 8S,T). This 
suggests that there was no change to the Tbx1+/−;Pax9+/− 4th PAA-derived phenotype caused by 
haploinsufficiency of Gbx2. 
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Figure 8. Gbx2 heterozygosity does not modify the Tbx1;Pax9 double heterozygous phenotype. (A-L) 
Tbx1, Pax9 and Gbx2 expression in E9.5-E10.5 control and Tbx1−/−, Pax9−/− and Gbx2−/− embryos (n≥3 
embryos per probe; 23–34 somites). (A) Tbx1 is expressed in the pharyngeal endoderm, mesoderm 
and ectoderm in control embryos. Tbx1 expression is absent in Tbx1−/− embryos (B), reduced in Pax9−/− 
embryos (C), and normal in Gbx2−/− embryos (D). (E) Pax9 is expressed in the pharyngeal endoderm 
in control embryos. Pax9 expression is reduced in Tbx1−/− embryos (F), absent in Pax9−/− embryos (G), 
and present in Gbx2−/− embryos (H). (I) Gbx2 is expressed in the pharyngeal endoderm in control 
embryos. Gbx2 expression is reduced in Tbx1−/− embryos (J), reduced in Pax9−/− embryos (K), and 
absent in Gbx2−/− embryos (L). (M–R) 3D reconstructions of E15.5–16.5 hearts from µCT datasets. (M) 
Control embryo with normal heart and aortic arch arteries. (N) Tbx1+/− embryo with aberrant right 
subclavian artery (A-RSA). (O) Tbx1+/−;Pax9+/− embryo with interrupted aortic arch type B (IAA-B) and 
cervical origin of the right subclavian artery (cRSA). (P) Tbx1+/−;Gbx2+/− embryo with a right-sided 
aortic arch (RAA) and A-RSA. (Q, R) Tbx1+/−;Pax9+/−+/−;Gbx2+/− embryos with IAA-B and A-RSA. (S,T) 
Graphical representation of IAA-B incidence (S) and 4th pharyngeal arch artery (PAA) incidence (T) 
in Tbx1;Pax9;Gbx2 embryos. *p < 0.05; **p < 0.001; ***p < 0 0001; Pearson chi-squared test for 
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associations with continuity correction. Scale bars: 500 µm in M-R; 50 µm in A–L. Abbreviations: Ao, 
aorta; AD, arterial duct; LCC, left common carotid artery; LSA, left subclavian artery; LV, left 
ventricle; me, mesoderm; pa, pharyngeal arch; pe, pharyngeal endoderm; p.ect, pharyngeal ectoderm; 
RCC, right common carotid artery; RSA, right subclavian artery; RV, right ventricle; s, somite. The 
somite numbers given in the legend reflect the range analysed for the whole study. The figure contains 
representative images only. 
Table 3. Number of cardiovascular defects observed in Tbx1;Gbx2;Pax9 mutant mice. 
Genotype n VSD 
RAA +/or 
A-RSA 
IAA-B +/− 
A-RSA 
4th PAA 
defect 
Tbx1+/− a 21 
2 
(10%) 
13 
(62%) 
1 
(5%) 
14 
(67%) 
Tbx1+/−; 
Pax9+/− b 
24 
5 
(21%) 
9 
(38%) 
15 
(63%)** 
24 
(100%) 
Tbx1+/−; Gbx2+/− 10 
3 
(30%) 
2 
(20%) 
1 
(10%) 
3 
(30%) 
Tbx1+/−; Gbx2+/−; Pax9+/− 8 
3 
(38%) 
4 
(50%) 
4 
(50%) 
8 
(100%) 
Embryos were collected from Tbx1+/−;Gbx2+/− and Pax9+/− crosses. Embryos were analysed by µCT at 
E13.5-E16.5. There was a statistically significant increase in the incidence of IAA-B in the Tbx1+/−;Pax9+/− 
embryos compared with the Tbx1+/− embryos. **p < 0.0001 (Pearson’s chi-squared test for associations 
with continuity correction). a New data (n = 3) combined with published MRI data (n = 19) [25]. b New 
data (n = 4) combined with published MRI data (n = 20) [25]. Abbreviations: A-RSA, aberrant right 
subclavian artery; IAA-B, interruption of the aortic arch, type B; RAA, right-sided aortic arch; VSD, 
perimembranous ventricular septal defect. 
4. Discussion 
In this study, we have employed imaging and gene interaction methodologies to provide an in-
depth analysis of the Gbx2 mutant cardiovascular phenotype throughout embryogenesis and 
demonstrate a genetic interaction with Pax9 in the pharyngeal endoderm. 
4.1. Gbx2-Null Mice 
Our analysis of the Gbx2-null cardiovascular phenotype revealed differences from two 
previously published papers. At mid-embryogenesis we found 71% of mutants had an abnormal 4th 
PAA, compared to 50% previously reported [28], and at foetal stages, we identified 64% of mutants 
had a cardiovascular defect, although none displayed IAA, compared to 39% previously reported 
where IAA was included [29]. One explanation for the cardiovascular phenotype discrepancy 
between studies is the Gbx2-null allele used. In the previously published studies, the neomycin 
selection cassette was retained in the first intron of Gbx2 [32,41], whereas it was removed from the 
allele used in our study. It is possible that the presence or absence of the neomycin cassette, which 
has been described to alter mutant mouse phenotypes [45], may have influenced the presentation of 
the cardiovascular phenotype. Alternatively, some cardiovascular defects may have been overlooked 
in the previous reports, or a subtle change in genetic background may influence the presentation of 
phenotypes. 
The cardiovascular structures predominantly affected in Gbx2-null embryos were the OFT, with 
DORV seen in 40% of mutants, and the 4th PAA-derived vessels, with 50% of mutants having an 
aberrant subclavian artery which was either retro-oesphageal or isolated. Although the formation of 
the 4th PAA was more frequently observed to be affected at mid-embryogenesis in Gbx2-null 
embryos, with this vessel seen to be absent or hypoplastic in 71% of mutants, this did not translate 
into an IAA-B phenotype at the foetal stage as would be expected if the left 4th PAA had failed to 
form. Immunolabelling of Gbx2−/− embryos showed a disorganisation of the endothelial cells within 
the 4th pharyngeal arch indicating that the 4th PAA fails to lumenise. This has also been previously 
described in Gbx2−/− embryos [29], as well as in other mouse models where the failure of the 4th PAA 
is a feature, for example, in Pax9−/− [25] and Tbx1 mutant [28] embryos. The discrepancy in 4th PAA 
J. Cardiovasc. Dev. Dis. 2020, 7, 20 19 of 24 
 
defects observed at an earlier developmental stage, yet not manifesting into a defect at a later stage, 
is a well-known phenomenon observed in Tbx1+/− embryos [25,28,46–49]. The recovery of the left 4th 
PAA may explain why we did not observe IAA-B in the Gbx2-null embryos. 
Patients that present with an incomplete reversal of the internal organs are diagnosed with 
heterotaxy which refers to any defect of left-right patterning and arrangement of the visceral organs. 
We identified previously unreported left-right patterning defects in a third of all Gbx2-null mutants 
examined. We did not find any change in Pitx2c expression in the left lateral plate mesoderm in Gbx2-
null embryos at E8.5, although we did not pre-select embryos for in situ hybridisation analysis based 
on any morphological abnormalities such as the orientation of the OFT. Gbx2 may function in left-
right patterning independently of Pitx2c. Left-right patterning defects are largely a result of 
abnormalities at the node of the primitive streak from E7.0 [50] and Gbx2 is expressed in all three 
germ layers at gastrulation in the posterior epiblast [30], a region encompassing the node. Overall, 
the number of Gbx2−/− embryos obtained was significantly lower than expected showing that more 
than half of Gbx2−/− embryos are lost prior to E8.5 in early embryogenesis, regardless of the 
accompanying Pax9 genotype. Early Gbx2 expression could, therefore, be critical for gastrulation and 
some embryos lacking Gbx2 may not proceed through development at this stage. The surviving 
embryos may then go on to develop left-right patterning and cardiovascular defects. Alternatively, 
Gbx2 may function downstream of Pitx2c to regulate the asymmetric development of the internal 
organs. Pitx2 is a regulator of gene expression [51] and the Pitx2c isoform plays an important role in 
the final stages of organ asymmetry [52] including aortic arch and outflow tract development [53,54]. 
Pitx2c mutant mice have OFT defects due to abnormal proliferation within the OFT myocardium [55]. 
Gbx2 may, therefore, be a downstream target of Pitx2c and further work is required to investigate this 
possibility. 
4.2. Genetic Interaction with Pax9 
Mice double heterozygous for Gbx2 and Pax9 were under-represented at weaning, and some 
were found to die at birth with cardiovascular defects. These data indicate there is a genetic 
interaction between Pax9 and Gbx2 in cardiovascular development. Interestingly, the RAA and IAA-
B phenotypes observed in Gbx2+/−;Pax9+/− neonates are commonly seen in Gbx2−/− and Pax9−/− mice 
respectively [25,29] but not in single heterozygous mice for these genes. When Gbx2−/− mice were also 
heterozygous for Pax9 (i.e., Gbx2−/−;Pax9+/−), 100% of embryos and neonates presented with a 
cardiovascular defect (significantly increased when compared to 64% of Gbx2−/− mice), including left-
right patterning defects, and there was a significantly increased incidence of IAA-B. Moreover, CAT 
was observed, a phenotype not previously identified in Gbx2−/− or Pax9−/− mice [25,29]. When we 
produced embryos null for Pax9 and heterozygous for Gbx2 (i.e., Gbx2+/−;Pax9−/−), or double knockouts, 
they all presented with typical Pax9-null defects but also additionally displayed CAT or AVSD. 
Embryos with a Pax9−/− genotype, however, did not display a left-right patterning defect as seen in 
the Gbx2−/− mice. Our data suggest that a reduction in bi-allelic Gbx2 and Pax9 expression leads to a 
modification of the phenotypes typically seen in the single-gene knockout mice. 
The cardiovascular defects observed in the Gbx2;Pax9 mutant mice such as AVSD, CAT and 
DORV are reminiscent of abnormal SHF development. Two-thirds of patients with heterotaxy have 
AVSD [56] and this defect arises from the failure of the SHF-derived dorsal mesenchymal protrusion 
to complete atrioventricular septation [57]. Patients with 22q11DS, where hemizygous expression of 
TBX1 underlies the observed cardiovascular defects, may present with CAT [58], and this phenotype 
is fully penetrant in Tbx1-null mice [34,59]. Tbx1 is expressed in the SHF [60], which overlaps with 
the pharyngeal endoderm [61], where Pax9 and Gbx2 are also expressed. It is therefore feasible that 
the pharyngeal endoderm expression of Pax9 and Gbx2 are influencing the formation of SHF-derived 
cardiovascular structures. There could also be a defective contribution in the Gbx2;Pax9 mutant mice 
from neural crest cells (NCC) migrating through the pharyngeal arches and into the OFT where they 
participate in septation [8]. Mouse models with NCC defects often present with CAT [62,63]. It has 
been reported that a reduced number of NCC are present within the caudal pharyngeal arches in 
Pax9-null embryos at E10.5 [25] and Gbx2-null mice show aberrant migration of NCC [28,29]. A NCC 
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defect, combined with deficiencies in the pharyngeal endoderm component of the SHF, could, 
therefore, become more penetrant on a Gbx2;Pax9 mutant background resulting in a higher incidence 
of the CAT and IAA-B phenotypes [64]. 
4.3. Gbx2 and Pax9 Interact in the Pharyngeal Endoderm 
Cardiovascular defects were observed when Gbx2 was conditionally deleted from the 
developing embryo using the Pax9Cre allele, and these were at a comparable level to that observed 
in the constitutive double heterozygous embryos, although the IAA-B phenotype was not seen. A 
higher incidence of 4th PAA defects, however, was seen in the conditional mutants at E10.5 when 
analysed by ink injection compared to those observed at foetal stages. As discussed above, it is well 
recognised that the 4th PAA can recover during development and there is not always a direct 
correlation to defects that are subsequently seen at the foetal stages. At the E10.5 stage, half the 
conditional Gbx2−/flox;Pax9Cre embryos presented with 4th PAA defects, whereas 100% of the 
constitutive Gbx2−/−;Pax9+/− embryos did, suggesting that either 4th PAA morphogenesis is only partly 
controlled from the pharyngeal endoderm or the Cre-mediated recombination of the Gbx2-floxed 
allele is not 100% efficient. Residual expression of Gbx2 RNA was observed in the pharyngeal 
endoderm of Gbx2−/flox;Pax9Cre embryos (Figure 7B), which may be due to the concomitant onset of 
Pax9Cre and Gbx2 expression at E8.5 resulting in a slight delay in Cre activity on the Gbx2-floxed 
allele. It has previously been shown that the deletion of Gbx2 from the pharyngeal ectoderm using 
AP2αCre mice resulted in a 47% penetrance of 4th PAA defects at E10.5 with the distribution of 
unilateral and bilateral 4th PAA defects in conditional endoderm and ectoderm mutants being very 
similar [28]. It is therefore tempting to speculate that Gbx2 expression from both pharyngeal epithelial 
tissues is required for correct 4th PAA morphogenesis. The incidence of defects seen at foetal and 
embryonic stages in the constitutive Gbx2−/−, Pax9−/− and Gbx2;Pax9 complex mutants was fairly 
concordant indicating that 4th PAA defects observed at E10.5 in these genotypes did proceed directly 
to arch artery defects at foetal stages. 
4.4. The Tbx1;Pax9 Double Heterozygous Phenotype is not Modulated by Gbx2 Haploinsufficiency 
Mice heterozygous for Tbx1 typically have defects affecting the 4th PAA such as IAA and A-
RSA [65], but have also been shown to present with further cardiac defects such as VSD [59,66]. Tbx1 
has been shown to genetically interact with Pax9 and Gbx2 in the pharyngeal endoderm and 
ectoderm, respectively [25,28]. We identified three PAX binding sites in a highly conserved region of 
the GBX2 locus, as well as a previously validated TBX binding site [42]. In luciferase assays, PAX9 
was able to activate the Gbx2 conserved region although TBX1 did not, and when PAX9 and TBX1 
were co-expressed, PAX9 was not able to activate the reporter. This suggests that PAX9 can activate 
Gbx2 through binding to the conserved region, whereas TBX1 acts as a repressor. However, to fully 
provide conclusive evidence for a molecular interaction for Gbx2 expression to be driven by Pax9 or 
Tbx1, further experiments would need to be performed such as an electromobility shift assay or 
chromatin immunoprecipitation experiments. Mutating the putative binding sites in the luciferase 
assay would also determine specificity. Gene expression is highly dynamic during cardiovascular 
development with constant switching between gene activation and suppression [67]. For example, 
Tbx1 acts as a poised enhancer to bind and keep DNA in the open state to then recruit other 
transcription or regulatory factors. It has been shown that Tbx1 recruits P53 to Gbx2 to modulate Gbx2 
expression through histone methylation [42]. As Tbx1 also regulates histone modification [68] it could 
have a potential role in controlling the timely activation of Gbx2 by Pax9 during cardiovascular 
development. 
Tbx1, Pax9 and Gbx2 are all expressed in the pharyngeal endoderm at E9.5 and E10.5, and could, 
therefore, function together in the endoderm which is acting as a signalling centre to interact with 
other tissue types required in PAA morphogenesis. Pax9 and Tbx1 were each downregulated in 
Tbx1−/− and Pax9−/− embryos respectively, which suggests that Tbx1 and Pax9 act in a non-hierarchal 
pathway [25]. Tbx1 and Pax9 expression in Gbx2−/− embryos, however, were unaffected indicating that 
these genes function hierarchically upstream of Gbx2. This is reflected in our phenotyping data where 
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we did not identify any difference in the incidence of 4th PAA-derived defects at foetal stages in 
Tbx1+/−; Pax9+/−;Gbx2+/− triple heterozygous mutants compared to Tbx1+/−; Pax9+/− double heterozygous 
mutants. Of note, however, in our study we only identified a low penetrance of 4th PAA-derived 
defects in Tbx1+/−;Gbx2+/− mutants, and only one incidence (10%) of IAA-B. This is in contrast to that 
previously shown for embryos of the same genotype where 27% of mutants (6 out of 22) had IAA-B 
[28]. This could possibly be attributed to the use of a different Gbx2 targeted allele as discussed above. 
5. Conclusions 
In summary, a genetic regulatory network comprising of Tbx1, Pax9 and Gbx2 is required to 
control morphogenesis of the arch arteries and the outflow tract of the developing cardiovascular 
system, and this interaction occurs, in part, within the pharyngeal epithelia at mid-embryogenesis in 
the mouse. An earlier role for Gbx2 in establishing left-right patterning requires further investigation. 
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